• NewAmsterdam Pharma appointed Robert W. Gunning as principal accounting officer, effective Aug. 10, 2026.
• Gunning joined as vice president, controller. He succeeds Louise Kooij, who will depart effective Aug. 31, 2026.
• He most recently served as interim controller and financial consultant at Altimmune from April 2026 to July 2026.
• Earlier roles include vice president finance and corporate controller at Y-mAbs Therapeutics, vice president controller at Excision Biotherapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-352186), on August 14, 2026, and is solely responsible for the information contained therein.